A new endocrine therapy strategy for bone metastasis of breast cancer: The effect of biological response modifiers and 22-oxacarcitriol on animal models

Abstract

To consider the treatment order of hormonal agents is very important in order to achieve a higher quality of life (QOL) and better survival rates in breast cancer patients with bone metastasis. Tamoxifen (TAM) or a luteinizing hormone-releasing hormone (LH-RH )analogue is the first-line, an LH-RH analogue (or TAM) the second-line, and medroxyprogesterone acetate(MPA) the third-line treatment in premenopausal patients with breast cancer. In postmenopausal patients, TAM (or toremifene) is the first-line, an aromatase inhibitor the second-line, and MPA the third-line treatment. In experimental studies using female Sprague-Dawley rats with 7, 12-dimethylbenz ma]anthracene (DMBA)-induced mammary carcinoma, biological response modifiers (BRM)(Krestin, Picibanil) and a vitamin D3 analogue, 22-oxacarcitriol (OCT)augmented the antitumor effect of hormonal agents. A combination of hormonal agents and BRM or OCT may be the endocrine therapy of choice for bone metastasis of breast cancer.

Polysaccharide-K (PSK) in Cancer - Old Story, New Possibilities?

“…It has been reported to be of potential benefit as adjuvant mono-or combination treatment in e.g. colorectal [10][11][12], breast [13][14], liver [15], pancreatic [16][17][18], gastric [19][20][21][22], esophageal [23], and lung cancer [24][25][26][27]. Furthermore, PSK has demonstrated minimal cytotoxicity or other side effects commonly associated with conventional anticancer treatments [28].…”